Since the inception of the company, the DoD has awarded Entegrion a total of nearly $88 million in contracts relating to leading edge study and advanced development of blood products and solutions.
Research Triangle Park, NC (PRWEB) October 09, 2014
North Carolina-based life sciences company, Entegrion, Inc., announces the award by the U.S. Department of Defense (DoD) of a $7.8 million contract to continue development of its extended storage life, platelet-derived hemostatic agent referred to as Stasix.
Entegrion’s Executive Vice President, Richard Martin, said, “We are pleased that DoD views this program as a healthcare priority for our military men and women. The ability to provide a platelet-derived hemostatic agent will make alternative therapies available for use in the field and in far forward hospitals to improve the survival of wounded soldiers.”
Physicians often administer units of platelets, an essential component of blood that initiates clotting activity, to patients whose platelets function poorly or have been depleted as a result of bleeding. Platelets will typically expire within five to seven days of collection. Entegrion’s Stasix particles are a platelet-derived hemostatic agent that will be used for non-compressible hemorrhage with a storage life of up to three years. This advanced technology could alter the care for wounded soldiers where fresh platelets are unavailable due to their rapid depletion of the primary hemostasis function.
“The development effort for this contract is focused on optimizing the manufacturing process for Stasix and its transfer to a cGMP manufacturing facility in preparation for human study,” added Michael Galiger, Entegrion’s Vice President of Operations. “Entegrion’s experience and expertise in this area was instrumental in securing this award.”
Executive Chairman, John B. Mowell, said, “Stasix represents a potentially viable solution to the platelet storage problem, and the importance of this technology is well documented by the fact that the DoD has provided substantial funding support toward the company’s development efforts in this field.” Mowell went on to report, “Since the inception of the company, the DoD has awarded Entegrion a total of nearly $88 million in contracts relating to leading edge study and advanced development of blood products and solutions.”
Entegrion, Inc. is a clinical stage life sciences product development company that is focused on improving the safety and availability of the world’s blood supply. Based in North Carolina’s Research Triangle Park, Entegrion offers patented technologies designed to overcome limitations in storage, safety, and availability of blood-derived products while preserving their functionality. Many of Entegrion’s advances in biologics are based on close collaborations with leading medical research institutions. Visit http://www.entegrion.com for more information.